| titleOfInvention |
Compound, pharmaceutical composition, and processes to inhibit tyrosine kinase activity pdgf, to inhibit tyrosine kinase lck activity, to inhibit cell proliferation, differentiation or mediator release in a patient, to treat a pathology linked to a hyperproliferative disorder , to treat restenosis, and, to treat inflammation in a patient |
| abstract |
"COMPOUND, PHARMACEUTICAL COMPOSITION, AND, PROCESSES TO INHIBIT THE ACTIVITY OF THYROSINE KINASE PDGF, TO INHIBIT THE ACTIVITY OF THYROSINE KINASE Lck, TO INHIBIT THE CELLULAR PROLIFERATION, DIFFERENTIATION OR LIBERATION OF A THERAPEUTIC THERAPY THERAPY HYPERPROLIFERATIVE, TO TREAT RESTENOSIS, AND TO TREAT INFLAMMATION IN A PATIENT "This invention is directed to quinoline / quinoxaline compounds that inhibit platelet-derived growth factor or p56 ^ 1ck ^ tyrosine kinase activity, to pharmaceutical compositions comprising these compounds and the use of these compounds to treat a patient suffering from, or subject to, disorders / conditions involving cell differentiation, proliferation, extracellular matrix production or mediator release and / or T cell activation and proliferation. |